【Case Study】Route, Solid-State, and Impurity Optimization (Small-Molecule API)
Learn more about our CMC Capability Route, Solid-State, and Impurity Optimization (Small-Molecule API) Program Type: Small-molecule APICMC Focus: Route optimization, solid-state control, impurity management Overview In a separate small-molecule program, Medicilon re-engineered the API synthetic route and solid form strategy to significantly improve manufacturability, safety, and analytical control. The work integrated process chemistry, solid-state science, […]
【Case Study】IND Completion in 12 Months (Small-Molecule NCE)
Learn more about our CMC Capability IND Completion in 12 Months (Small-Molecule NCE) Program Type: Small-molecule New Chemical Entity (NCE)Scope: End-to-end CMC (API process development, analytics, GMP manufacturing, regulatory documentation)Outcome: IND approval achieved ~12 months from contract signing Project Overview Medicilon supported a small-molecule NCE program with fully integrated CMC services, enabling IND approval within […]
Boston Non-Tumor Models Innovation
Learn more about our Non Tumor Model 1. Imiquimod (IMQ) Induced Psoriasis model Imiquimod (IMQ) Induced Psoriasis model. Female Balb/c mice (9 weeks old) were treated topically with imiquimod (IMQ) on the ear and dorsal skin for seven consecutive days (A). Psoriasis Area and Severity Index (PASI) (B), dorsal skin thickness change (%) (C), and […]
【White Paper】Navigating the DMPK Gauntlet: A Strategic Analysis of the Interconnected Challenges Shaping the Future of Drug Development
1.0 Executive Summary & Introduction The Drug Metabolism and Pharmacokinetics (DMPK) landscape is at a critical inflection point, shaped by the convergence of four powerful and interconnected forces: scientific complexity, technological disruption, regulatory and geopolitical upheaval, and intense business pressures. The traditional paradigms that once guided preclinical development are no longer sufficient. The rise of […]
【White Paper】Patient-Derived Xenograft Organoids: Advancements and Applications in Precision Oncology
Download our PDX Model poster presented at AACR 2025 1. Background of PDX-Derived Organoids 1.1 Historical evolution Patient-derived xenograft (PDX) models, pioneered in the 1960s by Rygaard and Poulsen, marked a significant advancement in oncology by preserving human tumor genetics in immunodeficient mice [1]. These models facilitated in vivo drug resistance studies but were hindered […]
【Blog】PDX-Derived Organoids: How This Mini-Tumor Transforming Cancer Research?
Imagine if we could grow tiny versions of a patient’s tumor in the lab, acting almost exactly like the real thing. PDXOs, the lab-growing 3D models, are not just cool science, they are changing how we discover and test disease treatment. Download our PDX Model poster presented at AACR 2025 So, what exactly are PDXOs? […]
Large Animal Models: Essential Tools in Disease Research
2024-12-02 Compared to rodents and non-human primates, large animal models such as dogs and miniature pigs offer unique advantages. They provide a balance between genetic, physiological, and structural similarities to humans, while maintaining relatively low experimental costs, making them invaluable in research and medical applications. These models are particularly effective in studying cardiovascular, neurological, dermatological, […]
PDXO Model: A Significant Advancement in Precision Oncology
2024-12-02 Patient-Derived Xenograft Organoids (PDXOs) are 3D organoid models derived from patient-derived xenograft (PDX) tumor tissues. Constructed using methods similar to those employed for patient-derived organoids (PDOs), PDXOs replicate the genetic, molecular, and structural features of the original tumors with exceptional accuracy. These models surpass traditional 2D cell cultures by preserving the complex internal architecture […]
Did You Know That Medicilon Can Handle DMPK Studies?
2024-10-22 Medicilon Preclinical Pharmacokinetics Department has many professional scientists with rich theoretical knowledge and experimental experience for experimental design, implementation, bioanalysis and data analysis. Our Pharmacokinetics Lab has passed the NMPA GLP certification. Following the guiding principles of ICH, NMPA and FDA . The lab offers in vivo and in vitro pharmacokinetic tests according to […]
Medicilon’s GLP-1 New Drug R&D Service
2023-06-12 Type 2 diabetes is a progressive disease. The disease course is primarily characterized by a decline in β-cell function and worsening of insulin resistance. Therefore, various antidiabetic agents are under research and development. The hypoglycemic strategy has also shifted from “sugar control” to both “sugar control” and “heart protection”. GLP-1R agonists can improve left […]
